| Micro-channel |
 |
|
|
|
|
|
| |
| The report shows that the medical device industry has stable growth risk and investment stability |
| |
| Author：中國銘鉉 企劃部 Release Time：2017-9-1 11:00:05 Number Browse：788 |
| |
Medical device companies, the report revealed on September 1, reported that medical device companies are growing almost across the board.The steady performance and good development prospects have attracted the attention of the capital, and some of the start-up medical device enterprises have been invested heavily in venture capital.
In the first half of the year, medical equipment is one of the best performing subfields in the pharmaceutical industry.In the first half of the year, the company posted A revenue of 21.83 billion yuan, up 30% from A year earlier.Net profit of 495 million yuan, up 31 percent year on year;The operating income of fish jumping medical service reached 18.61 billion yuan, up 30% from the same period last year.Net profit of 398 million yuan, up 20% year-on-year.Minimally invasive healthcare, which is listed on the Hong Kong stock exchange, saw revenues of $217 million, up 12.5 percent year-on-year.Net profit of $20.6 million, up 272% year on year.
In addition to professional medical device companies, the medical device plate in the comprehensive pharmaceutical group is also very dazzling.Fosun medicine center daily news, according to the company agent "the Da Vinci surgical robot" he continue to maintain rapid growth, in mainland China and Hong Kong for more than 12800 units, an increase of about 60%.At present, fosun medicine and "the Da Vinci surgical robot technology and brand owners intuitive medical equipment companies in the United States to set up joint venture intuitive fosun industrial and commercial registration has been completed, will speed up the development and popularization of high-end medical technology in China.
"In the first half of the year, the new health reform policy and its supporting measures continued to be detailed and promoted, and the domestic medical equipment industry was promoted steadily.In the international market, the European Union has issued new medical device law, which provides new opportunities for the international medical device companies with strong innovation ability and excellent product quality.Chang zhaohua, chairman of minimally invasive medicine, said.
The good performance of listed medical device enterprises attracts venture capital to bet on start-ups.In late August, minimally invasive medical's focus on the business heart valves, a subsidiary of minimally invasive heart medical technology co., LTD., with 2.1 billion yuan of the valuation of the financing agreement signed a $430 million, investors including huaxing capital owned by huajie tianjin, cicc's cicc PuCheng, teri and huatai securities owned by China.
Before the middle of August, with independent research and development of magnetron gastroscope capsule robot AnHan medical technology co., LTD., also announced from large and medium-sized investments, softbank China capital six investment institutions such as a combined $100 million of investment, for landscape to develop market and new product research and development.
The risk capital is optimistic about medical devices, not only in the amount of investment of hundreds of millions of dollars, but also in the development stage of the investment target.As an example, it is mainly engaged in the development and manufacture of high-end cardiac valve interventional instruments, which can be used for the treatment of severe calcified aortic stenosis.Aortic stenosis is one of the most common and most severe valvular disease in the elderly, with 83,000 implanted in the world via catheter aortic valve implantation in 2016.The number of such operations worldwide is expected to increase fourfold in the next decade as the population ages.
It is worth noting that VitaFlow, a therapeutic product developed by minimally invasive heart, is currently in clinical trials and has not yet been officially launched."This is the first time, a subsidiary of the minimally invasive with clinical stage product line successful foreign financing, fully reflects investors involved in valve products and market confidence," minimally invasive, chief technology officer, says Dr July 1.According to the development schedule, VitaFlow is expected to be approved by the CFDA in 2018.
Big investment, the development of medical device enterprises will play a huge impetus.AnHan JiPengSong medical chairman, said AnHan existing in medical research capsule robot dozens of products, the future will make the digestive tract, thanks to the Internet medical big data platform, promote the artificial intelligence application in the field of medical image, the capsule endoscopy client all over the country can enjoy the remote service.
|
| |
Previous article：Medical equipment procurement, please do not discriminate against low bid!
Next article：The price of the first day of medical adjustment in henan has been adjusted
|
| |
|
|
